Table 3.
The current clinical trials with CAR therapy targeting CSCs.
| Target | NCT | Phase | Current status | Condition | Year |
|---|---|---|---|---|---|
| CD44 | NCT04427449 | I/II | Recruiting | Cancers (CD44v6+) | 2020 |
| NCT04097301 | I/II | Terminated | AML, MM | 2019 | |
| CD133 | NCT03473457 | NA | Terminated | AML | 2018 |
| NCT02541370 | I/II | Completed | AM | 2015 | |
| CD123 | NCT04014881 | I | Recruiting | AML | 2019 |
| NCT04599543 | I | Not yet recruiting | AML | 2020 | |
| NCT02937103 | I/II | Unknown | MM | 2016 | |
| NCT04265963 | I/II | Recruiting | AML | 2020 | |
| NCT03190278 | I | Recruiting | AML | 2022 | |
| EpCAM | NCT02915445 | I | Recruiting | Nasopharyngeal/Breast cancer | 2016 |
| NCT03563326 | I | Recruiting | Gastric cancer | 2018 | |
| NCT05028933 | I | Recruiting | Digestive system cancers | 2022 | |
| NCT02729493 | NA | Unknown | Liver cancer | 2016 | |
| CD117 | NCT03473457 | NA | Terminated | AML | 2018 |
| NCT03356782 | I/II | Recruiting | Sarcoma | 2017 | |
| ROR1 | NCT05274451 | I | Recruiting | Solid tumors | 2022 |
| NCT02706392 | I | Terminated | Cancers (ROR1+) | 2016 | |
| CXCR4 | NCT04727008 | I | Not yet recruiting | MM | 2021 |
AM, advanced malignancies; MM, multiple myeloma; NA, not available; ROR1, receptor tyrosine kinase-like orphan receptor 1.